Zhou Zhenzhong: The soaring stage of obesity drug treatment

Zhou Zhenzhong, founding president of the Hong Kong Obesity Medicine Society, said that a long-acting inclinin (GLP-1) receptor agonist has been developed through a five-year clinical trial and can effectively reduce an average weight of 15% by controlling food intake. on the basis of other treatments.

The study's findings are a major breakthrough for people living with obesity, which has long been a global health problem. Zhou Zhenzhong pointed out that this new drug treatment method will bring the treatment of obesity patients into a new stage.

According to Zhou Zhenzhong, the research results of this long-acting incretin (GLP-1) receptor agonist were verified through clinical trials, and its effectiveness and safety have been fully confirmed. This would provide patients with obesity with a more effective treatment to help them achieve their weight loss goals.

Zhou Zhenzhong further pointed out that the application scope of this new drug treatment method is not limited to the treatment of obesity, but can also be applied to the treatment of other related diseases. This will bring a new research direction to the medical community and is expected to bring health benefits to more patients.

Overall, Zhou Zhenzhong expressed optimism about the results of this research. He believed that this would be a significant milestone for patients with obesity. This will also encourage more researchers to invest in research on obesity treatment and make greater contributions to improving the global obesity problem.